About AM-Pharma
AM-Pharma is a company based in Bunnik (Netherlands) founded in 2001. AM-Pharma has raised $316.15 million across 8 funding rounds from investors including AbbVie, Pfizer and Takeda Pharmaceuticals. AM-Pharma offers products and services including Ilofotase Alfa. AM-Pharma operates in a competitive market with competitors including Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
- Headquarter Bunnik, Netherlands
- SectorsHealthcare
- Website am-pharma.com
- Social LinkedIn
- Legal Name Am-Pharma B.V.
- Total Equity Funding$316.15M (USD)
in 8 rounds
- Latest Funding Round$25.43M (USD), Series F
Mar 2020
- InvestorsAbbVie
& 14 more
Products & Services of AM-Pharma
AM-Pharma offers a comprehensive portfolio of products and services, including Ilofotase Alfa.
Enzyme therapy for treating acute kidney injury and hypophosphatasia.
Funding Insights of AM-Pharma
AM-Pharma has successfully raised a total of $316.15M across 8 strategic funding rounds. The most recent funding activity was a Series F round of $25.43 million completed in March 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $316.15M
- Total Rounds 8
- Last Round Series F — $25.43M
- First Round $3.45M
(Aug 2007)
- Investors Count 15
All 8 funding rounds of AM-Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2020 | $26.54M | Debt – Conventional | – | – | |
| Mar 2020 | $25.43M | Series F | – | Cowen | |
| Jul 2019 | $133M | Series F | – | Andera Partners, Life Sciences Partners | |
| May 2015 | $87.5M | Series E | – | Pfizer | – |
| Sep 2014 | $15.73M | Series D | – | Gilde Healthcare | |
| Sep 2011 | $40M | Series D | – | Kurma Partners, Ysios Capital | |
| May 2008 | $11.03M | Series C | – | Forbion, Inventages | – |
| Aug 2007 | $3.45M | Series C | – | Forbion, Inventages | – |
15 investors in total: 15 institutional.
Investors in AM-Pharma
AM-Pharma has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include AbbVie, Pfizer and Takeda Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Capital is provided to firms for growth, buyouts, and acquisitions. | 2001 | anderapartners.com | Paris, France | |
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
Venture capital firm focused on lifescience and healthcare sectors | – | forbion.com | Naarden, Netherlands | |
Ysios Capital is recognized as a leading life sciences investor. | – | ysioscapital.com | Barcelona, Spain | |
Private equity and venture captial firm focused on healthcare sectors | – | gildehealthcare.com | Cambridge, United States | |
Biotech startups are funded through venture capital in life sciences. | 2009 | kurmapartners.com | Paris, France | |
Venture capital is invested in innovative drug development companies. | – | pureosbio.com | Pfäffikon, Switzerland | |
Equity investments are provided to low and middle market companies. | 1997 | idinvest.com | Paris, France | |
- | – | bbbiotechventures.com | - | |
- | – | inventages.com | - |
Investor details for AM-Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AM-Pharma
3 people are tracked at AM-Pharma (3 in leadership).
| Name | Role | Group |
|---|---|---|
Juliane Bernholz | Chief Executive Officer | Leadership |
Peter Verwayen | Vice President Finance | Leadership |
Sjoert van der Berg | Sr Director Finance | Leadership |
Complete people profiles for AM-Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of AM-Pharma
3 dated milestones of AM-Pharma across 19 years, from founding to its latest funding, stage changes and deals.
- Founded AM-Pharma is founded.
- Funding First funding round of $3.5M.
- Funding Latest funding round, Series F, of $25.4M.
Competitors of AM-Pharma
AM-Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| merck.com | 1891 | Kenilworth, United Kingdom | – | 781 | Pharmaceutical products are manufactured and marketed worldwide. | |
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| abbvie.com | 2012 | Chicago, United States | – | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | |
| gilead.com | 1987 | Foster, United States | – | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | |
| lilly.com | 1876 | United States | – | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. | |
| vrtx.com | 1989 | United States | – | 5,400 | Developer of drugs for the treatment of multiple disorders | |
| unither.com | 1998 | Silver Spring, United States | – | 1,168 | Treatments for chronic and life-threatening diseases are developed and commercialized. | |
| morphosys.com | 1992 | Planegg, Germany | – | 732 | Therapeutic antibodies for cancer and other diseases are developed. | |
| roche.com | 1896 | Basel, Switzerland | – | 2,382 | Pharmaceuticals and diagnostics kits are developed for various diseases. | |
| eisai.com | 1941 | Tokyo, Japan | – | 10,419 | Drugs for oncology and neurological disorders are developed by Eisai. |
Detailed competitors of AM-Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of AM-Pharma
The website of AM-Pharma (am-pharma.com) receives about 4.4K visits a month.
- Monthly visits4.4K
▲ 34% vs previous month
Websites whose visitors overlap most with AM-Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
idc-wick.com | idc-wick.com | 100% | – | – | – |
| imgenex.com | 100% | – | – | View details | |
peprotechec.com | peprotechec.com | 100% | – | – | – |
biotrend.com | biotrend.com | 100% | – | #4,074,352 | – |
| microbix.com | 100% | 4.6K | #4,143,140 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 21 similar websites and full traffic analytics for AM-Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 21 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Am-Pharma
Complete news archive for AM-Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to AM-Pharma
10 companies that operate in the same segment as AM-Pharma (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about AM-Pharma
AM-Pharma was founded in 2001 and raised its 1st funding round 6 years after it was founded.
AM-Pharma is headquartered in Bunnik, Netherlands. It is registered at Bunnik, Utrecht, Netherlands.
AM-Pharma is a funded company, having raised a total of $316.15M across 8 funding rounds to date. The company's 1st funding round was a Series C of $3.45M, raised on Aug 2007.
AM-Pharma was founded in 2001 in Bunnik, Netherlands, within the biotechnology sector. Therapeutics targeting inflammatory and infectious diseases are developed, with a focus on endogenous proteins, protein-derived peptides, and naturally occurring human molecules. Operations center on clinical-stage candidates, including alkaline phosphatase in phase 2 trials for acute kidney injury and ulcerative colitis, as well as hLF1-11 for drug-resistant hospital-acquired infections.
AM-Pharma's top competitors include Merck, Roivant Sciences and AbbVie.
AM-Pharma offers Ilofotase Alfa.
AM-Pharma has 15 investors. Key investors include AbbVie, Pfizer, Takeda Pharmaceuticals, TD Securities, and European Investment Bank.
AM-Pharma operates through Am-Pharma B.V..